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Abstract: Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t
(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treat-
ment represents the paradigm of molecular therapy of cancer. Since the development of the
tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has
dramatically changed, with a stunning improvement in the quality of life and response
rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable
to target the most immature cellular component of CML, the CML stem cell. This review
summarizes new insights into the mechanisms of resistance to TKIs.
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Introduction
Chronic Myeloid Leukaemia (CML) is the paradigm of bench-to-bedside transla-
tional research.1–6 CML was among the first cancers to be clearly associated with a
genetic lesion, namely the Philadelphia Chromosome, able to generate the chimeric
BCR-ABL protein. A plethora of studies with cellular and murine models7 con-
verged on the assumption that one single oncogenic gene - BCR-ABL - can drive a
potent leukaemogenic signal.3 For this reason, BCR-ABL has been intensively
studied as a perfect druggable target, leading to the development of imatinib,
which quickly raised the clinical arena.8 CML remains the most successfully treated
disease with a TKI,9 while in other cancers, responses to other specific TKIs are
less pronounced. Therefore, understanding the unique biological features of CML
should provide new insights into the management of other cancers. In this respect,
resistance to TKIs has been generally considered a consequence of the insensitivity
of cancer stem cells to these drugs10 and, therefore, CML remains a perfect battle-
field to investigate biological behaviours of these elusive cells.11 A lot of evidence
has clearly demonstrated that CML stem cells remain unaffected by BCR-ABL
TKIs, as extensively reviewed.10,12–14 In particular, TKIs are able to enter CML
stem cells, to inhibit BCR-ABL, but are not able to promote their apoptosis.14
The resistance of CML stem cells to TKIs is a very challenging issue that has
been investigated in great depth over the years.15 Resolving this problem may not
affect CML patients,16 who highly benefit from TKI therapy, but may significantly
improve our knowledge on leukaemia stem cells, and may improve cancer therapies
in general, specifically in those tumours where kinase inhibitors or other molecular
approaches fail to achieve convincing clinical results.
This review focuses on mechanisms that affect CML stem cells.
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Cooperating Oncogenes
For many years, various groups have focused their attention
on different pathways that may cooperate with BCR-ABL
or may act independently from BCR-ABL in promoting
resistance of CML stem cells to TKIs. Here, we will review
the most well-known pathways.
NF-kB
The contribution of the NF-kB signalling pathway has
been intensively investigated in CML, and in many other
cancers.17 NF-kB is a transcriptional pathway able to
promote various biological processes, favouring cell
growth, survival, metastatization and resistance to
chemotherapy.18 The most common form of NF-kB is
the heterodimer p65/p50, which becomes entrapped in
the cytoplasm by the IkB-alpha protein, therefore blocking
its transcriptional activity. Upon stimulation, the IkB-alpha
protein is phosphorylated at serine residues by the IKK-
kinase complex, promoting its proteosomal degradation,
and enabling NF-kB to shuttle into the nucleus. Various
studies have attributed an essential role for NF-kB in
BCR-ABL-mediated signalling,19,20 as we have also
recently reviewed.17
Besides playing a pivotal role in the bulky population
of CML cells, NF-kB has been also investigated in the
stem cell compartment. In particular, two groups have
shown that CML stem cells are able to produce and secrete
both transforming growth factor-β (TGF-β)21,22 and
tumour necrosis factor-α (TNF-α),23 which - in turn -
support the survival status of the same cells. While these
observations suggest that NF-kB can play a remarkable
role in stem cells, it is not known whether NF-kB inhibi-
tors may play a specific role in promoting CML stem cell
eradication.
Hedgehog Pathway
Among the many pathways able to modulate stem cell
maintenance, hedgehog signalling undoubtedly plays a
pivotal role.24 Three Hedgehog homologues, namely
Desert (DHH), Indian (IHH) and Sonic (SHH), bind to
the hedgehog receptor - Patched (Ptc) - promoting cell
proliferation and survival in a complex mechanism.
While the DHH and IHH pathways have been found to
be deregulated in various tumours, SHH signalling has
been found to be altered in CML and in leukaemia pro-
genitor cells. Targeting this signalling pathway offers a
chance to eliminate CML stem cells, while sparing normal
haematopoietic stem cells (HSC).25 However, to our
knowledge, to date, no data from clinical trials have been
published with Hedgehog inhibitors in the CML context.
Beta-Catenin
The Wnt/β-catenin pathway is, historically, a major stem
cell pathway, able to modulate both quiescence and main-
tenance, as extensively reviewed.26 It was demonstrated
that β-catenin is involved in various aspects of CML
biology, including maintenance of CML stem cells, thus
promoting the study of the beta-catenin pathway as a
druggable pathway in CML.27
PP2A
The tumour suppressor PP2A has been extensively studied
in the context of CML stem cells. In particular, BCR-ABL
was shown to inhibit the phosphatase activity of PP2A and
its reactivation was found to be associated with a marked
growth suppression and apoptosis induction.28
Remarkably, a PP2A activator named FTY720 (2-
amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydro-
chloride) displayed potentially relevant implications from
a therapeutic standpoint.29,30 Similar conclusions were
achieved with the clinically validated PP2A inhibitors
LB100 and LB102.31
Additional Pathways
Various signal transduction pathways have been shown to
modulate BCR-ABL signalling8,32 and to promote resistance
to TKI in a BCR-ABL independent manner. Among them,
the CK233,34 and Alox535 pathways, along with others, were
also associated with the possibility of specific inhibition. It
should, however, be noted that most of these pathways have
not been investigated in CML stem cell settings.
Tumour Suppressors
While no tumour suppressors have been consistently found
mutated or deleted in the chronic phase of CML, in recent
years, various tumour suppressors have been found to be
functionally inactive in CML, as we have previously
reviewed.36 Identifying inactive tumour suppressors and the
mechanisms of inactivation may open new therapeutic oppor-
tunities. Indeed, restoring the function of an inactive tumour
suppressor may represent a strong pro-apoptotic signal.
PML
The promyelocytic leukaemia (PML) tumour suppressor
protein is an essential component of nuclear bodies and is
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involved in various cellular processes. PML has been
shown to play an important role in regulating CML stem
cells.37 PML is a key regulator of the quiescence of these
cells, irrespective of the BCR-ABL signal. The relevance
of these observations has been associated with the ability
of arsenic trioxide to target PML to degradation. Arsenic
trioxide has been demonstrated to promote the exit of
CML stem cells from the quiescent status, rendering
these cells susceptible to apoptosis. For this rational, clin-
ical trials are still ongoing.
PTEN
PTEN is a tumour suppressor involved in regulating various
cellular processes, such as the maintenance of genomic stabi-
lity, cell survival, migration, proliferation and metabolism.38
While originally described as a phosphatase, able to depho-
sphorylate PIP3, it also displays phosphatase-independent
functions. HSC rely on functional PTEN, as extensively
studied.39,40 In addition, PTEN integrity is mandatory in
CML.41 The involvement of PTEN in CML is strictly con-
nected to its correct cellular compartmentalization. We
observed that, while in CML progenitor cells PTEN is mostly
expressed in the cytoplasm, in the CML stem cell compart-
ment, PTEN is retained in the nuclear pool.42 Regulating
PTEN compartmentalization depends on a functional PML/
HAUSP network, which is maximized in the stem cell com-
partment. Shuttling of PTEN is indeed associated with
changes in cellular behaviours of various cancers.42,43 PTEN
cellular compartmentation can be modulated by arsenic -tri-
oxide, which affects the PML/HAUSP network, as we pre-
viously described. More recently, strategies for targeting the
Enhancers of zeste homologue 2 (EZH2), a core catalytic
subunit of polycomb repressive complex (PRC2) were
shown tomodulate PTEN expression in the stem cell compart-
ment, with important therapeutical implications.44
FoxO
Forkhead box subgroup O (FoxO) is a family of tran-
scription factors (TFs) that play an essential role in
regulating cancer stem cells.45 As described for PTEN
and p53, FOXOs are mainly deregulated through func-
tional modification of cellular compartmentalization. It
has been widely demonstrated that inhibition of FoxO1
and 3a, through cytoplasmic shuttling, supports the
growth and inhibition of cell death in CD34+ CML
cells. Conversely, leukaemia-initiating cells (LICs) are
enriched in FoxO3a nuclear localization mediated by a
decrease in Akt phosphorylation.46,47
Morgana
Morgana/chp-1 plays an essential role in mouse embryonic
development, involved in the regulation of centrosome dupli-
cation and genomic stability.18,48 Morgana binds to ROCKI
and ROCK II, favouring inhibition of ROCKII kinase activ-
ity. Recently, we have demonstrated that morgana ± mice
developed a fatal myeloproliferative disorder, resembling
atypical CML.49 In an extended analysis, we also demon-
strated that some CML patients may also display reduced
morgana protein levels in the most immature cellular com-
partment. Therefore, ROCK activity was increased in these
patients with a reduced response to TKI treatment.
TP53
TP53 is one of the most studied and well-known tumour
suppressors.50,51 The role of p53 in CML was originally
assessed when searching for genetic inactivation. TP53 was
indeed discovered to bemutated/deleted in a fraction of CML
blast crisis.52 However, it was also clear that the role of p53
in cancer is more complex, including functional inactivation
through delocalization and post-translational modifications.
P53 has been shown to be functionally inactivated
through direct binding with IkB-alpha in the CML
context.53 More recently, by investigations with proteo-
mics, transcriptomics and network analyses, p53 was
shown to be deregulated in the stem cell compartment,
together with c-Myc.54 Pharmacological modulation of
both p53 and c-Myc levels has been associated with a
marked induction in CML stem cell apoptosis.
Epigenetics And Modifiers
Histone deacetylase inhibitors (HDACi) are epigenetic
modifiers that, in vitro, promote growth arrest and apoptosis
of myeloid tumour cells.55 For this reason, many HDACi
have been tested in CML and in CML stem cells,56 and
various trials have been designed to test HDCA in associa-
tion with TKI. To our knowledge, no relevant data have,
however, been published following these trials.
Yet, epigenetic reprogramming remains a challenging
topic in CML stem cells, as recently observed with
EZH2.57 Taken together, these data suggest that further
investigations are necessary to identify the best epigenetic
modifiers in CML and the best combinatorial approach.
CML Stem Cell Metabolism
Cellularmetabolism reprogramming is an emerging hallmark
for cancer survival and cancer stem cell biology.58 While
normal cells use glucose to produce energy by mitochondrial
Dovepress Carrà et al
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oxidative phosphorylation, cancer cells have been shown to
increase glucose uptake and promote aerobic glycolysis,
originally described as the Warburg effect. This metabolic
shift has also been described in CML, where it appears to be
therapeutically modulated.59 The mTOR pathway has been
extensively studied as a major determinant of the anabolic
and catabolic processes in normal and cancer cells,60 and the
mTORpathway has also been intensively studied in the CML
setting.61 The kinase - AMPK - has been described as an
essential regulator of mTOR and cellular metabolism and
shown to play an important role in CML pathogenesis62 and
resistance to TKIs.63 Notably, AMPK appeared to be targe-
table in CML.64 Finally, and in agreement with the metabolic
reprogramming of CML cells, antidiabetic drugs have also
been shown to play important roles in this disease. In addi-
tion, Metformin,65,66 glitazones have been recently studied
due to their ability to target CML stem cells.67,68
microRNAs
Various microRNAs (miRNA) have been reported to play a
role in CML and, in particular, in the stem cell compartment:69
miR-126,70 miR-29a-3p, miR-494-3p and miR-660-5p,71 and
others. More recently, a challenging hsa-mir183/EGR1/E2F1
axis has been reported to directly control CML stem cell
behaviour.72 Most of these miRNAs have been extensively
reviewed elsewhere.69,73–77
Cluster Of Differentiation
Various biomarkers defined as Cluster of Differentiation
(CD) have been recognized as specifically expressed in the
stem cell compartment.78 The cytokine targeting surface
enzyme dipeptidylpeptidase-IV (DPPIV/CD26) has been
shown to be mostly expressed in the stem cell compart-
ment of CML.78–83 Interestingly, CD26 expression appears
to be associated with the expression of Polycomb BMI1
protein.84 The IL2 receptor CD25 was also shown to be
over-expressed in CML cells and - in particular - in the
stem cell compartment.85–87 While the function of most of
these biomarkers remains to be defined in the CML stem
cell population, selective expression in these cells may
offer a challenging therapeutic implication. Monoclonal
antibodies may possibly be developed to specifically target
these CD and potentially reach the stem cells of CML.
Stroma
Interaction of HSC and leukaemia stem cells with bone
marrow microenvironments is indispensable for the initia-
tion, maintenance, and progression of CML, and may also
affect the sensitivity to therapies.88 Furthermore, the role
of the stem cell niche in CML leukaemogenesis has been
investigated in-depth, highlighting the role of Cxcl12 in
the regulation of quiescence of CML.89
Autophagy
Autophagy is a process that is evolutionally conserved to
allow recycling of cytoplasmic components through the
formation of the autophagosome. These vesicles are driven
into lysosomes where they are degraded.90,91 Inhibiting
autophagy has been shown to play an important role in
cancer therapy.92 In line with these observations, autop-
hagy inhibitors have been tested as strategies to target
CML stem cells alone93 or in combination with mTOR
inhibitors61 and PARP inhibitors.94
Immune System
Aberrant immune-inhibitory responses have been observed
in CML patients at diagnosis,95 and the immune cellular
context has been shown to impact CML therapy96 and/or
affect immune surveillance.97 Similarly, TKIs have been
shown to affect the immune system.98 Various cytokines
known to play a role in the immune system, such as
CXCR2 and CXCL4, have been shown to regulate the
survival of CML stem cells.99 While further investigations
are needed in this context, these observations indicate a
pivotal role of the immune system in each phase of CML
maintenance and, therefore, suggest the variegation of
therapeutical implications. In this respect, following the
increase in the use of Chimeric Antigen Receptor - engi-
neered T cells - in the clinical scenario, it was also shown
that CAR-T directed toward IL1RAP could represent an
efficient approach for targeting CML stem cells.100 In
addition, checkpoint inhibitors have been discussed as
potential relevant targets in CML therapy.101
Parallel to the role of the immune system, the intriguing
role of inflammation (a mixture of immune system regulators
and cytokines) has also been investigated as a determinant
for CML stem cell maintenance and/or development.102
Discussion
In this review we have reported various pathways and/or
mechanisms that have been recognized to modulate CML
stem cell behaviour. For each of these pathways, specific
inhibitors have been identified, allowing the proposal of a
combinatorial therapy with TKIs with the aim of eradicating
CML stem cells. Various clinical trials have been designed
for this purpose,10 but results are still pending. Data obtained
from the clinical scenario will allow identification of
Carrà et al Dovepress
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pathways with relevant roles in the CML stem cell compart-
ment from the plethora of cooperating pathways. CML
response rates suggest that combinatorial therapies will
only be proposed to those patients resistant to TKIs; however,
deciphering mechanisms of insensitivity of CML stem cells
to TKIs may shed new light on how to efficiently treat other
cancers. It is worth noting that other Philadelphia-positive
types of Leukaemia, such as Acute Lymphoblastic
Leukaemia, are much less sensitive to BCR-ABLTKIs, and
the reason is far from being understood. Moreover, other
cancers with other active tyrosine kinases did not respond
to specific TKIs with the same efficacy described for CML.
Knowing the correct approach for targeting stem cells should
enhance the response rates in various tumours.
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